SNDX Q4 2020 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$380,000+0.0% YoY

Gross Profit

$379,00099.7% margin

Operating Income

-$20M-5226.3% margin

Net Income

-$20M-5374.5% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+0.3%

Cash Flow

Operating Cash Flow

-$16M

Free Cash Flow

-$16M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$301M

Total Liabilities

$48M

Stockholders' Equity

$252M

Cash & Equivalents

$115M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$380,000	$380,000	+0.0%
Gross Profit	$379,000	$380,000	-0.3%
Operating Income	-$20M	-$14M	-39.8%
Net Income	-$20M	-$14M	-45.9%